<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791243</url>
  </required_header>
  <id_info>
    <org_study_id>PM1542</org_study_id>
    <nct_id>NCT02791243</nct_id>
  </id_info>
  <brief_title>Photosensitization Study in Androgenetic Alopecia</brief_title>
  <official_title>A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polichem S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polichem S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the potential for induction of photosensitization by P-3074 0.25%&#xD;
      finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a&#xD;
      negative control (0.9% sodium chloride, NaCl)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy male volunteers, drawn from the general population, will be treated with P-3074&#xD;
      solution, placebo vehicle control and 0.9% sodium chloride USP (negative control) by using 6&#xD;
      induction applications on the back area and Ultraviolet A (UVA)/Ultraviolet B (UVB)&#xD;
      irradiations during the 3 week induction period, a 10 day rest period, and a challenge phase&#xD;
      of a 24-hour patch application, UVA and UVB irradiation followed by evaluation of&#xD;
      photosensitization over the subsequent 72 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2016</start_date>
  <completion_date type="Actual">June 27, 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Potential for induction of photosensitization</measure>
    <time_frame>from day 4 to day 42</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Finasteride 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 0.2 ml of P-3074 (0.25% finasteride)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Finasteride 0.25%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>approximately 0.2 ml of the vehicle cutaneous solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>approximately 0.2 ml of 0.9% aqueous NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride 0.25%</intervention_name>
    <description>Cutaneous solution of finasteride 0.25%</description>
    <arm_group_label>Finasteride 0.25%</arm_group_label>
    <other_name>P-3074</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Finasteride 0.25%</intervention_name>
    <description>vehicle cutaneous solution of P-3074</description>
    <arm_group_label>Placebo for Finasteride 0.25%</arm_group_label>
    <other_name>vehicle cutaneous solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Negative Control</intervention_name>
    <description>0.9% aqueous NaCl</description>
    <arm_group_label>Negative Control</arm_group_label>
    <other_name>0.9% aqueous NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males aged 18 to 65.&#xD;
&#xD;
          2. Good general health, as assessed by verbal medical history and brief physical&#xD;
             examination of the skin.&#xD;
&#xD;
          3. Fitzpatrick Skin Type I-IV, determined by interview at screening.&#xD;
&#xD;
          4. Willing to use a double-barrier methods (for example, a condom or a diaphragm plus&#xD;
             spermicide) during sexual intercourse with a female partner while participating in the&#xD;
             study.&#xD;
&#xD;
          5. Male subjects will need to confirm method and length of time for method of birth&#xD;
             control for female partners.&#xD;
&#xD;
          6. Fully informed of the risks of entering the study and willing to provide written&#xD;
             consent to enter the study.&#xD;
&#xD;
          7. Willing to follow study rules, which include: no sun exposure (for example, no&#xD;
             swimming, sunbathing, or tanning beds), avoidance of activities that would cause&#xD;
             excessive sweating, no use of lotions, creams, or oils on the back area&#xD;
&#xD;
          8. Must be willing not to change current brand of personal care products such as soaps,&#xD;
             body washes, laundry detergent, body sprays, body spritzes, etc. while participating&#xD;
             on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MED ≤ 2.5 SED for Fitzpatrick Skin Types I and II or MED ≤ 4.0 SED for Fitzpatrick&#xD;
             Skin Types III and IV&#xD;
&#xD;
          2. Type I Insulin-dependent diabetes&#xD;
&#xD;
          3. Mastectomy for cancer involving removal of lymph nodes draining the test site.&#xD;
&#xD;
          4. Clinically significant skin diseases which may contraindicate participation, including&#xD;
             psoriasis, eczema, atopic dermatitis, and active skin cancer.&#xD;
&#xD;
          5. Use of any photosensitizing medications or supplements, such as but not limited to&#xD;
             sulfa drugs, tetracyclines, phenothiazines, thiazides, antiemetics and St. John's&#xD;
             Wort.&#xD;
&#xD;
          6. Any medical conditions caused or affected by sunlight (UV), such as but not limited to&#xD;
             solar urticarial and polymorphous light eruptions.&#xD;
&#xD;
          7. Active immunologic disorders.&#xD;
&#xD;
          8. Routine use of anti-inflammatory, immunosuppressive or antihistamine medications (81&#xD;
             mg aspirin is acceptable).&#xD;
&#xD;
          9. Participation in a patch test or soap chamber test within the past 4 weeks.&#xD;
&#xD;
         10. History of significant sensitivity or allergy to adhesive bandages, tapes, etc.&#xD;
&#xD;
         11. Use of finasteride (oral and/or topical), within 6 months prior to the screening&#xD;
             visit.&#xD;
&#xD;
         12. Contraindications to finasteride therapy or intolerance of finasteride.&#xD;
&#xD;
         13. History of sensitivity to skin solution products.&#xD;
&#xD;
         14. Hair, tattoos, pigmentation, scars, moles or other conditions at the areas to be&#xD;
             patched that may interfere with patch application, tolerability, or postapplication&#xD;
             evaluations.&#xD;
&#xD;
         15. Participation in a clinical trial or receipt of an investigational medication within 4&#xD;
             weeks of the study.&#xD;
&#xD;
         16. Current treatment with allergy injections.&#xD;
&#xD;
         17. History of severe asthma.&#xD;
&#xD;
         18. Chronic or active liver disease [alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &gt; 1.5x upper limit of normal (ULN)]&#xD;
&#xD;
         19. Neutrophils &lt; 1500 cells/mm3&#xD;
&#xD;
         20. Clinically significant chronic illness, which could place the subject at increased&#xD;
             risk during participation or result in inappropriate dermal response during the study&#xD;
             in the opinion of the Investigator.&#xD;
&#xD;
         21. History of alcohol or drug abuse within 1 year of the study.&#xD;
&#xD;
         22. Any condition the Investigator believes would interfere with the evaluation of the&#xD;
             subject, or may put the subject at undue risk.&#xD;
&#xD;
         23. Judged by the investigator to be unsuitable for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Carr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princeton Consumer Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princeton Consumer Research Inc.</name>
      <address>
        <city>Chelmsford,</city>
        <state>Essex</state>
        <zip>CM2 6UA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
    <mesh_term>Photosensitivity Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

